All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
On May 18, 2020, positive interim results were announced from the multi-center, open-label, phase I study of TRPH-222 (NCT03682796). This trial investigated the efficacy and safety of the next-generation antibody-drug conjugate, TRPH-222, in heavily pre-treated patients with relapsed and/or refractory B-cell lymphoma (non-Hodgkin lymphoma; NHL). The primary aim was to determine the maximum tolerated dose of TRPH-222; the secondary aims were to assess the safety, anti-tumor activity, and the pharmacokinetics. 1, 2
Data from the trial demonstrated early signs of a potential therapeutic benefit in the dose-escalation stage. Of the 19 heavily pretreated patients with NHL, five patients achieved a complete response at doses of 0.6 – 4.2 mg/kg every 3 weeks. Tumor reductions were seen in patients with both indolent and aggressive disease. Patients with follicular, diffuse large cell, and mantle cell lymphoma maintained a durable response. TRPH-222 was well-tolerated with a benign safety profile. The trial is currently ongoing with dose level of 10 mg/kg every 3 weeks. 1, 2
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Preparing for CAR T-cell therapy: patient selection, bridging therapies and lymphodepletion
CAR T-cell therapies represent a highly effective treatment option for certain patients with hematologic malignancies; however, the most optimal bridging and...
Preliminary results from phase I studies of CD20 × CD3 bispecific antibodies in R/R B-cell non-Hodgkin lymphoma
For patients with B-cell non-Hodgkin lymphoma (NHL) who relapse or become refractory to chemotherapy and anti-CD20 immunotherapy, there...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox